stroke. Brain stem stroke syndrome
Conditions
Interventions
Intervention 1: Intervention group: Patients are randomly selected by an unaware individual and are divided into two intervention groups receiving treatment with alteplase at appropriate doses. Patie
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with acute ischemic stroke treated with alteplase or tenectplase after the onset of symptoms Patient age over 18 years Patients who can receive intravenous thrombolytics within 4.5 hours of ischemic stroke
Exclusion criteria
Exclusion criteria: Patients with hemorrhagic stroke Patient age under 18 years Patients with ischemic stroke without tPA treatment Patients with a history of bleeding disorders, recent surgery or acute comorbidities Patients who have received endovascular thrombectomy Patients with contraindications to tPA and in cases where the risk of bleeding outweighs the benefits of pharmacotherapy (since tPA increases the risk of bleeding, patients with a history of recent intracranial hemorrhage (ICH[1]) or intracranial hemorrhage, subarachnoid hemorrhage , structural vascular lesion of the brain, intracranial neoplasm, active internal bleeding, recent intracranial or intraspinal surgery, uncontrolled high blood pressure and serious head trauma within the past 3 months, may not be able to receive this drug).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stroke severity. Timepoint: 24 hours, 7 days, and 90 days after the initiation of treatment. Method of measurement: Primary Outcome Measure:The number of patients with an mRS score of 0-1 at 3 months.Secondary Outcomes Include:Change in mRS classification at 3 months.Reduction in the National Institutes of Health Stroke Scale (NIHSS) by 8 points or more or achieving a score of 0-1 within 24 hours.Symptomatic intracerebral hemorrhage within 36 hours.Adverse events and mortality within 90 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes include changes in mRS classification at 3 months. Timepoint: 3 month. Method of measurement: Primary Outcome Measure:The number of patients with an mRS score of 0-1 at 3 months.Secondary Outcomes Include:Changes in mRS classification at 3 months.A reduction in the National Institutes of Health Stroke Scale (NIHSS) by 8 points or more or achieving a score of 0-1 within 24 hours.Symptomatic intracerebral hemorrhage within 36 hours.;Primary Outcome Measure:The number of patients with an mRS score of 0-1 at 3 months.Secondary Outcomes Include:Changes in mRS classification at 3 months.A reduction in the National Institutes of Health Stroke Scale (NIHSS) by 8 points or more or achieving a score of 0-1 within 24 hours.Symptomatic intracerebral hemorrhage within 36 hours. Timepoint: 3 month. Method of measurement: Secondry outcome variables classification mRS after 3 month. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDavood shalilahmadi
Ahvaz University of Medical Sciences
Outcome results
None listed